Article Sidebar
Views pdf: 128
STUDY ON SEVERAL PROGNOSTIC FACTORS FOR CHEMORADIOTHERAPY OUTCOME OF NASOPHARYNGEAL CANCER STAGE II - III
Main Article Content
Abstract
Objectives: To evaluate several prognostic factors treatment outcome of nasopharyngeal cancer stage II-III with a weekly dose of Cisplatin in combination with Intensity Modulated Radiation Therapy. Subjects and methods: An uncontrolled clinical interventional study on 68 nasopharyngeal cancer (NPC) patients withstage II-III. These patients received Intensity Modulated Radiation Therapy combination with Cisplatin 40 mg/m2 body skin weekly for 6 weeks of radiotherapy, with or without adjuvant chemotherapy added. Results: The average overall survival time of the study: 34.4 ± 9.15 months. Overall survival rates: 12 months, 24 months, and 36 months were 97%, 91.1%, and 88%, respectively. Conclusion: Interruption of chemoradiotherapy is a prognostic factor for the overall survival time. Tumor volume and EBV reactivation before treatment were different, but they were not prognostic factors of treatment outcome in this study.
Article Details
Keywords
Nasopharyngeal cancer, Chemoradiotherapy, Intensity Modulated Radiotherapy, Prognostic factors, Overall survival time
References
2. Đặng Huy Quốc Thịnh (2012). Hóa Xạ Trị Đồng Thời Carcinoma Vòm Hầu Giai Đoạn Tiến Xa Tại Chỗ - Tại Vùng. Luận án tiến sĩ Y học. Trường Đại học Y Dược TP HCM.
3. Chen L., Hu C.S., Chen X.Z., et al (2012). Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial. Lancet Oncol; 13(2):163-171. doi:10.1016/S1470-2045(11)70320-5
4. Chen M., Yin L., Wu J., et al (2015). Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma. Biomed Res Int. doi:10.1155/2015/617949
5. Chen Y.P., Liu X., Zhou Q., et al (2021). Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet (London, England); 398(10297): 303-313. doi:10.1016/S0140-6736(21) 01123-5
6. Du T., Xiao J., Qiu Z., Wu K. (2019). The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. PLoS One; 14(7). doi:10.1371/JOURNAL.PONE.0219611
7. Lee N.Y., Zhang E., Pfister D.G., et al (2012). Phase II Study of the Addition of Bevacizumab to Standard Chemoradiation for Loco-regionally Advanced Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group (RTOG) Trial 0615 HHS Public Access. Lancet Oncol; 131016(211):172-180. doi:10.1016/S1470-2045(11)70303-5.Phase
8. Mazul A.L., Stepan K.O., Barrett T.F., et al (2020). Duration of radiation therapy is associated with worse survival in head and neck cancer. Oral Oncol; 108:104819. doi:10.1016/J. ORALONCOLOGY.2020.104819
9. Sung H., Ferlay J., Siegel R.L., et al (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin; 71(3):209-249. doi:10.3322/CAAC.21660
10.Wee, J. et al (2005). Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. Journal of clinical oncology : Official journal of the American Society of Clinical Oncology; 23(27):6730-6738. Available at: https://doi.org/10.1200/JCO.2005.16.790.